Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Average Rating of “Hold” by Brokerages

Revance Therapeutics, Inc. (NASDAQ:RVNC) has received an average recommendation of “Hold” from the nine brokerages that are presently covering the stock, MarketBeat.com reports. Eight analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $8.39.

RVNC has been the topic of a number of research reports. Mizuho decreased their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research note on Tuesday, December 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. HC Wainwright reaffirmed a “neutral” rating and set a $6.60 price objective on shares of Revance Therapeutics in a research report on Friday, November 8th. Barclays cut their price objective on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Monday, December 23rd. Finally, StockNews.com began coverage on Revance Therapeutics in a research report on Saturday, February 22nd. They set a “hold” rating on the stock.

Revance Therapeutics Price Performance

NASDAQ:RVNC opened at $3.65 on Thursday. The stock’s fifty day moving average is $3.45 and its two-hundred day moving average is $4.59. Revance Therapeutics has a 52 week low of $2.30 and a 52 week high of $7.56. The stock has a market capitalization of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90.

Hedge Funds Weigh In On Revance Therapeutics

Large investors have recently bought and sold shares of the business. Natixis purchased a new position in Revance Therapeutics in the fourth quarter valued at $31,000. Two Sigma Securities LLC purchased a new position in Revance Therapeutics in the fourth quarter valued at $35,000. Alpine Global Management LLC purchased a new position in Revance Therapeutics in the fourth quarter valued at $37,000. FORA Capital LLC purchased a new position in Revance Therapeutics in the third quarter valued at $54,000. Finally, RPO LLC purchased a new position in Revance Therapeutics in the fourth quarter valued at $55,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.